Eli Lilly reported strong Q2 results with robust revenue growth led by key drugs Mounjaro and Zepbound. The company raised its 2026 revenue guidance to $85–87 billion, supported by volume gains despite price declines, and expects continued margin expansion. A major catalyst is the upcoming Retatrutide drug, with a Biologics License Application planned for early 2027 and potential applications in new therapeutic areas. The stock is considered attractively valued with a potential 23.7% upside as Eli Lilly continues to outperform its sector.
Nxera Pharma announced a net profit of JPY 1,591 million (US$10.1 million) for Q2 2026, reversing a prior loss due to multiple milestone payments from partners like Neurocrine, AbbVie, and Lilly. The company progressed regulatory approvals and commer...
Eli Lilly and Novo Nordisk both beat Q2 estimates and raised their full-year outlooks, but investors favored Lilly, boosting its shares while punishing Novo. Lilly leads the obesity drug market with a 60.9% U.S. share, driven by strong sales of Mounj...
Eli Lilly reported a 48% year-on-year revenue increase to $22.97 billion, driven by strong sales of GLP-1 drugs Mounjaro and Zepbound, which make up about 65% of total revenue. The company raised its 2026 revenue guidance to $85 billion–$87 billion, ...
The Dow Jones surged 650 points to a new high of 54,740, and the S&P 500 also reached an all-time high, rising 0.7% to 7,790. However, tech stocks showed weakness with the Nasdaq up only 0.35%, dragged down by a 10% plunge in SpaceX shares after its ...
Eli Lilly reported Q2 revenue of $22.97 billion, up 48% year-over-year, surpassing Wall Street estimates driven by strong sales of Mounjaro and Zepbound weight-loss and diabetes treatments. Non-GAAP EPS rose 33% to $8.38, beating expectations. The co...
